Title: Edrecolomab
CAS Registry Number: 156586-89-9
CAS Name: Anti-(human colon cancer tumor-associated antigen) immunoglobulin G2a (mouse monoclonal 17-1ag2a-chain) disulfide with mouse monoclonal 17-1A light chain, dimer
Additional Names: 17-1A antibody
Trademarks: Panorex (Centocor)
Literature References: Murine monoclonal IgG2a antibody directed against the cell surface glycoprotein CO17-1A, a human tumor associated antigen expressed on malignant and normal epithelial cells. Prepn: M. Herlyn et al., Proc. Natl. Acad. Sci. USA 76, 1438 (1979). Pharmacology: D. Herlyn, H. Koprowski, ibid. 79, 4761 (1982). Clinical studies in colorectal cancer: G. Riethmüller et al., Lancet 343, 1177 (1994); eidem, J. Clin. Oncol. 16, 1788 (1998). Review of prepn and pharmacology: A. H. Ross et al., Immunol. Ser. 43, 107-122 (1989); and clinical experience: J. C. Adkins, C. M. Spencer, Drugs 56, 619-626 (1998).
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Monoclonal Antibodies.
Edrophonium Chloride EDTA EEDQ Efalizumab Efaproxiral

Edrecolomab ?
Monoclonal antibody
Type Whole antibody
Source Mouse
Target EpCAM (17-1A)
Clinical data
Trade names Panorex
Legal status  ?
CAS number 156586-89-9 N
ATC code L01XC01
Chemical data
Formula  ?
 N (what is this?)  (verify)

Edrecolomab (MAb17-1A, trade name Panorex) is a mouse-derived monoclonal antibody targeting the cell-surface glycoprotein EpCAM (17-1A), which is expressed on epithelial tissues and on various carcinomas.

Preliminary studies had shown promise of a possible use in patients with stage III colorectal carcinoma (with metastasis to the lymph nodes).[1][2] However, when put to a phase III study (2,761 patients) it did not provide any benefit when compared to conventional chemotherapeutic agents.[3] No effect has been demonstrated for stage II (locally advanced cancer without spread to the lymph nodes) colon cancer.[4]

Edrecolomab was well tolerated in these studies and as such research has now concentrated on whether it can be of any use in other forms of cancer.